Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Cell-Based Therapy
  • Published:

Cell-Based Therapy

Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse

Abstract

We have selected a well-characterized human renal cell carcinoma (RCC) line as the basis for development of a genetically engineered tumor cell vaccine to be applied in an allogeneic setting. This cell line was genetically modified by retroviral transduction to express B7.1 costimulatory molecules. The unmodified tumor cells and B7.1-expressing tumor cells were compared for their ability to induce tumor-associated responses in allogeneic peripheral blood mononuclear cells (PBMC) of two normal control donors having single MHC class I allele matches with the tumor cells. PBMC primed using B7.1-modified tumor cells showed a preponderance of CD3+CD8+ cytotoxic T lymphocytes (CTL) that proliferated over extended periods of time in mixed lymphocyte tumor cell (MLTC) cultures. Strong cytolytic activity developed in the primed populations and included allospecific CTL with specificity for mismatched HLA-A, -B and -C molecules. Nevertheless, it was possible to isolate CTL clones that were able to lyse tumor cells but not lymphoblastoid cells that expressed all the corresponding allospecificities. Thus, induction of complex allospecific responses did not hinder the development of tumor-associated CTL in vitro. These results support the use of this genetically modified allogeneic tumor cell line for vaccination of partial-MHC matched RCC patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Noessner E, Schendel DJ . Autologous and allogeneic tumor cell vaccines. In: Blankenstein Th (ed) Gene Therapy, Principles and Applications1 Birkhäuser Verlag: Basel 1999 299–312

    Google Scholar 

  2. Hui K, Grosveld F, Festenstein H . Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation Nature 1984 311: 750–752

    Article  CAS  PubMed  Google Scholar 

  3. Hui KM, Sim T, Foo TT, Oei AA . Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene J Immunol 1989 143: 3835–3843

    CAS  PubMed  Google Scholar 

  4. Nabel GJ, Felgner PL . Direct gene transfer for immunotherapy and immunization Trends Biotechnol 1993 11: 211–215

    Article  CAS  PubMed  Google Scholar 

  5. Kayaga J et al. Anti-tumor activity against B16F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine Gene Therapy 1999 6: 1475–1481

    Article  CAS  PubMed  Google Scholar 

  6. Toes REM et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res 1996 56: 3782–3787

    CAS  PubMed  Google Scholar 

  7. Mandelboim O, Vadai E, Feldman M, Eisenbach L . Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells Gene Therapy 1995 2: 757–765

    CAS  PubMed  Google Scholar 

  8. Schendel DJ et al. Tumor-specific lysis of human renal cell carcinomas by tumor- nfiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines J Immunol 1993 151: 4209–4220

    CAS  PubMed  Google Scholar 

  9. Jantzer P, Schendel DJ . Human renal cell carcinoma antigen-specific cytotoxic T lymphocytes: antigen-driven selection and long-term persistence in vivo Cancer Res 1998 58: 3078–3086

    CAS  PubMed  Google Scholar 

  10. Schendel DJ et al. Cellular and molecular analyses of MHC-restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy J Mol Med 1997 75: 400–413

    Article  CAS  PubMed  Google Scholar 

  11. Chen L et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71: 1093–1102

    Article  CAS  PubMed  Google Scholar 

  12. Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells (see comments) Science 1993 259: 368–370

    Article  CAS  PubMed  Google Scholar 

  13. Li Y, McGowan P, Hellström KE, Chen L . Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma J Immunol 1994 153: 421–428

    CAS  PubMed  Google Scholar 

  14. Hellstrom KE, Hellstrom I, Chen L . Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995 145: 123–145

    Article  CAS  PubMed  Google Scholar 

  15. Johnston JV et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes J Exp Med 1996 183: 791–800

    Article  CAS  PubMed  Google Scholar 

  16. Martin-Fontecha A et al. Heterogeneous effects of B7–1 and B7–2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors Eur J Immunol 1996 26: 1851–1859

    Article  CAS  PubMed  Google Scholar 

  17. Leong CC et al. Transfection of the gene for B7–1 but not B7–2 can induce immunity to murine malignant mesothelioma Int J Cancer 1997 71: 476–482

    Article  CAS  PubMed  Google Scholar 

  18. Hodge JW, Abrams S, Schlom J, Kantor JA . Induction of antitumor immunity by recombinant vaccinia viruses expressing B7–1 or B7–2 costimulatory molecules Cancer Res 1994 54: 5552–5555

    CAS  PubMed  Google Scholar 

  19. Sulé-Suso J et al. A B7–1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes Eur J Immunol 1995 25: 2737–2742

    Article  PubMed  Google Scholar 

  20. Antonia SJ et al. B7–1 expression by a non-antigen presenting cell-derived tumor Cancer Res 1995 55: 2253–2256

    CAS  PubMed  Google Scholar 

  21. Bain C et al. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells Int J Cancer 1996 67: 769–776

    Article  CAS  PubMed  Google Scholar 

  22. Wang YC et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7–1 (CD80) costimulation J Immunother Emphasis Tumor Immunol 1996 19: 1–8

    Article  PubMed  Google Scholar 

  23. Yang SX et al. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells Cancer Res 1997 57: 1561–1568

    CAS  PubMed  Google Scholar 

  24. Hirano N et al. Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)-transduced leukemic cells Hum Gene Ther 1997 8: 1375–1384

    Article  CAS  PubMed  Google Scholar 

  25. Jung D et al. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes Hum Gene Ther 1998 9: 53–62

    Article  CAS  PubMed  Google Scholar 

  26. Motzer RJ, Bander NH, Nanus DM . Renal cell carcinoma New Engl J Med 1996 335: 865–875

    Article  CAS  PubMed  Google Scholar 

  27. Boon T, Coulie PG, Van den Eynde B . Tumor antigens recognized by T cells Immunol Today 1997 18: 267–268

    Article  CAS  PubMed  Google Scholar 

  28. Panelli MC et al. A tumor-infiltrating lymphocyte for a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12 J Immunol 2000 164: 4382–4392

    Article  CAS  PubMed  Google Scholar 

  29. Moebius U et al. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations Eur J Immunol 1991 21: 1793–1800

    Article  CAS  PubMed  Google Scholar 

  30. Döhring C, Angman L, Spagnoli G, Lanzavecchia A . T-helper and accessory cell independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector Int J Cancer 1994 57: 754–759

    Article  PubMed  Google Scholar 

  31. Ramarathinam L, Castle M, Wu Y, Liu Y . T cell costimulation with B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells J Exp Med 1994 179: 1205–1214

    Article  CAS  PubMed  Google Scholar 

  32. Fenton RG, Turcovski-Corrales SM, Taub DD . Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines J Immunother 1998 21: 95–108

    Article  CAS  PubMed  Google Scholar 

  33. Imro MA et al. Human melanoma cells transfected with the B7–2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro Hum Gene Ther 1998 9: 1335–1344

    Article  CAS  PubMed  Google Scholar 

  34. Meuer SC et al. Construction of immunogenic tumor cell surfaces by somatic gene transfer Recent Results Cancer Res 1998 144: 78–85

    Article  CAS  PubMed  Google Scholar 

  35. Meyer GC et al. Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigen (HLA)-A2.1+-matched situation Cancer Gene Ther 1999 6: 282–288

    Article  CAS  PubMed  Google Scholar 

  36. Meyer GC et al. Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells Adv Exp Med Biol 1998 451: 195–202

    Article  CAS  PubMed  Google Scholar 

  37. Schendel DJ, Maget B, Falk CS, Wank R . Human CD8+ T lymphocytes. In: Lefkovits I (ed) The Immunology Methods Manual Academic Press: London 1997 670–690

    Google Scholar 

  38. Köhler I et al. Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL-4 sharing a DNA binding motif with an interferon-gamma induced nuclear binding factor FEBS Lett 1994 345: 187–192

    Article  PubMed  Google Scholar 

  39. Daniel PT et al. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis J Immunol 1997 159: 3808–3815

    CAS  PubMed  Google Scholar 

  40. Schendel DJ, Wank R, Dupont B . Standardization of the human in vitro cell-mediated lympholysis technique Tissue Antigens 1979 13: 112–120

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants of the Deutsche Forschungsgemeinschaft (Ho 1596/3–2) and the Bundesministerium für Bildung, Forschung und Technologie (01GE9624, 01KV9506, and 01EC9406). We thank S Lupton for the vector tgls(+) HyTK and A Gärtner for excellent technical support.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schendel, D., Frankenberger, B., Jantzer, P. et al. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7, 2007–2014 (2000). https://doi.org/10.1038/sj.gt.3301349

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301349

Keywords

This article is cited by

Search

Quick links